Hologic Launches 3DQuorum™ Imaging Technology, Powered by Genius AI™, in Europe
26.10.2020 15:00:00 EET | Business Wire | Press release
Hologic, Inc. (Nasdaq: HOLX) today announced the commercial availability in Europe of its 3DQuorum™ Imaging Technology, Powered by Genius AI™. The innovation was designed to help improve mammography efficiency and workflow, which is critical as clinics strive to manage the backlog of women whose routine breast screening was delayed due to the COVID-19 lockdown.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005023/en/
3DQuorum™ Imaging Technology, Powered by Genius AI™ (Graphic: Business Wire)
The 3DQuorum technology uses Genius AI-powered analytics to reconstruct high-resolution 3D data to produce 6mm “SmartSlices.” These analytics identify clinically relevant regions of interest and preserve important features during reconstruction of the SmartSlices.1,2 SmartSlices expedite read time by reducing the number of images for radiologists to review, without compromising image quality, sensitivity or accuracy.1,2 With 3DQuorum technology, the number of 3D images to review is reduced by two-thirds, saving an average of one hour per eight hours of daily image interpretation time.1,2,3
“As we continue to operate in this new landscape, radiologists are facing the dual challenge of a serious backlog of women who need routine breast screening as well as a screening process that is lengthier due to COVID-19 protection measures,” said Jan Verstreken, Hologic's Group President, International. “The more efficient workflow of 3DQuorum, is urgently necessary to help radiologists meet this challenge. This solution is a strong example of how Hologic continues to streamline workflow for radiologists by improving the reading experience without sacrificing accuracy or quality of work – a balance that our customers have come to expect.”
In addition to the implications associated with the COVID-19 virus, radiologists are facing a growing need for improved workflow efficiency as digital breast tomosynthesis (DBT) becomes the gold standard for screening in Europe. Recently, the European Commission Initiative on Breast Cancer (EBIC) guidelines on breast cancer screening and diagnosis recommended for the first time the use of either DBT or digital mammography in screening. However, DBT creates an influx of large file sizes and images that can lengthen the image reading process for radiologists. This creates a need for solutions like 3DQuorum technology to help streamline workflow where possible.
More information on 3DQuorum technology can be found here and by visiting www.3dimensionsmammography.eu/3dquorum.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
3DQuorum™ Imaging Technology, Powered by Genius AI™, and Clarity HD™ high resolution imaging technology are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to womenshealth@hologic.com.
SOURCE: Hologic, Inc.
1 Tech File: TFL-00059
2 Report: CSR-00116
3 Physician Labeling: MAN-06153
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005023/en/
Contact information
Media Contact:
Jane Mazur
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael Watts
+1 858.410.8588
michael.watts@hologic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smead Capital Management Extends International Value Strategy to Global Investors Through New Fund10.6.2026 10:00:00 EEST | Press release
Smead Capital Management, a Phoenix-based investment management firm and a leader in value investing, today announced the launch of the Smead Global ex-US Value UCITS Fund designed to provide global investors with access to a product modeled after the firm’s long-standing Smead International Value Strategy. The Smead Global ex-US Value UCITS Fund is domiciled in Luxembourg. Investors can access the fund through Smead Capital Management’s website and it is available to professional and qualified investors through the fund’s transfer agent. The strategy that the Smead Global ex-US Value UCITS Fund is modeled after, the Smead International Value Strategy, has been a core contributor to Smead Capital Management’s outstanding performance for over a decade. Like all Smead products, the Global ex-US Value UCITS Fund will be built on Smead’s eight investment criteria and a disciplined, contrarian, value approach. “Many investors around the world believe non-US companies cannot produce attracti
Dodge Opens Orders for the Next Generation Charger in Europe10.6.2026 10:00:00 EEST | Press release
An Icon Enters Its Next Generation This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609386800/en/ Celebrating its 60th anniversary this year, Dodge opens a bold new chapter in Europe with the launch of the next-generation Dodge Charger, bringing one of America’s most iconic muscle cars back to European roads through a new multi-energy lineup engineered to deliver performance and attitude without compromise. Six decades after the original Charger helped define the muscle car era, this new eighth-generation model evolves the formula for a new generation of drivers while remaining unmistakably Dodge in character, design and presence. Available with both all-electric and gasoline powertrains, the new Charger reflects Dodge’s performance-first philosophy: different powertrains, same muscle car DNA. The next-generation Charger arrives in Europe in both two-door and four-door configurations, combining iconic proportions, wide-body
Roquette Showcases Scalable Drug Delivery Innovations at CPHI China 202610.6.2026 10:00:00 EEST | Press release
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, will showcase its comprehensive portfolio of innovative drug delivery solutions at CPHI & PMEC China 2026, taking place June 16-18 at the Shanghai New International Expo Centre (SNIEC). Under the theme “One Roquette for Innovations,” Roquette’s Health & Pharma Solutions Business Unit will exhibit at booth E3D26, highlighting how its deep scientific expertise and technical capabilities enable pharmaceutical companies to turn promising formulations into scalable commercial realities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610596225/en/ Visit Roquette at booth E3D26 to meet with its team of experts “As the pharmaceutical industry accelerates innovation, from GLP-1 therapies to complex biologics, the pressure to deliver manufacturing reliability, consistent supply, and robust formulations at scale has never been greater,” said Angela S
Trustd Brings Know Your Carrier to Market as Freight Fraud Costs European Supply Chains Over €1bn10.6.2026 09:01:00 EEST | Press release
Trustd, the digital identity and credentials verification platform for transport and logistics, is bringing to market Know Your Carrier (KYC), a web-based verification tool that lets shippers and 3PLs get an instant risk signal on carriers quoting for work via email in seconds. Cargo crime across EMEA has risen 438% in three years. More than 108,000 supply chain thefts were recorded across the region in the last two years. Of the 5% that reported a financial loss, the combined value exceeded €1bn, equivalent to €1.3m every 24 hours. Know Your Carrier draws on Trustd's expertise in digital identity verification to address a problem that has until now had no industry-wide solution. The web-based tool plugs into existing workflows with no installation or integration. Users enter an email address and, where available, a VAT number. The tool checks email legitimacy and domain matching, business registration data, adverse media, sanctions and court judgments, and Trustd’s own growing network
Sofinnova Partners Launches Collaboration with AWS to Scale AI Across Life Sciences Innovation10.6.2026 09:00:00 EEST | Press release
Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced a collaboration with Amazon Web Services (AWS), to embed AI more deeply across its investment platform and portfolio companies. The collaboration supports Sofinnova.AI, the firm’s initiative to integrate AI across its core activities, from sourcing and evaluating investments to supporting company building. At the center of this effort is Sofia, Sofinnova's proprietary AI platform, which will be extended beyond internal use to include a founder-facing version. Through this collaboration, Sofinnova-backed startups will gain access to tailored AWS resources and technical enablement, helping them move faster from early research to development and commercialization. “AI is becoming central to how new therapies are discovered, developed, and brought to patients,” said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners. “With Sofinnova.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom